Proactive Investors - Run By Investors For Investors

ArQule shares boosted by positive results from study of cancer-fighting inhibitor ARQ 531

ArQule said ARQ 531 demonstrated substantial anti-tumor activity and a favorable safety profile
cell
ArQule develops targeted therapeutics to treat cancers and other rare diseases

Shares of ArQule Inc (NASDAQ:ARQL) rose by double-digits Friday after announcing preliminary yet positive results from a Phase 1 dose escalation study for its cancer-fighting inhibitor ARQ 531.

The study focused on using ARQ 531 to treat both wild type and C481S-mutant Bruton’s tyrosine kinase in patients with relapsed or refractory hematologic malignancies which are leukemias and lymphomas.

ArQuale said ARQ 531 demonstrated substantial anti-tumor activity and a favorable safety profile.

The company’s stock recently traded up 35% to $8.44 a share.

READ: Oppenheimer initiates coverage on ArQule with an Outperform rating and US$7 price target

ArQule presented the results at the 2019 European Hematology Association (EHA) Annual Meeting in Amsterdam, the Netherlands.

“The profile of ARQ 531 continues to strengthen, and we are delighted to be able to demonstrate such compelling clinical activity at a well-tolerated dose in patients who have already exhausted available therapies,” said Dr Brian Schwartz, chief medical officer. “We are now focused on finalizing the recommended phase 2 dose and planning for the expansion of our clinical efforts with ARQ 531 into later stage trials across multiple indications as a single agent and as a combination therapy.”

ArQle, based in Burlington, Massachusetts, is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and other rare diseases.

-- updates stock price --

Contact the author: [email protected]stors.com

Follow him on Twitter @PatrickMGraham

View full ARQL profile View Profile

ArQule Timeline

Related Articles

Sativa
June 07 2019
Geremy Thomas, founder and chief executive of Sativa, said the company has "delivered expeditiously on its investment promise to the market"
LX2 analyzer
May 07 2019
Armed with promising study results and proven technology, LexaGene is getting ready to launch the LX2 Genetic Analyzer to underserved markets valued at an estimated US$40 billion
An illustration of Ozop's BLIF technique
March 30 2019
A key area of focus for the West Palm Beach, Florida, company is development of balloon lumbar interbody fusion (BLIF) technology
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use